Allowing for the completion of the recap with preferential subscription rights
03/07/24 -"We have incorporated the second capital increase of €237m with preferential subscription rights following its completion. The number of shares has been fine-tuned from 355m to 356m. Note that we had ..."
Pages
51
Language
English
Published on
03/07/24
You may also be interested by these reports :
27/02/26
bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 ...
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...